Paper Details
- Home
- Paper Details
Efficacy and safety of raltegravir plus lamivudine maintenance therapy.
Author: AlcamiJose, AmbrosioniJuan, BerrocalLeire, BlanchJordi, BlancoJose L, BorjabadBeatriz, CalvoJulia, ChiviteIvan, De La MoraLorena, De LazzariElisa, FoncillasAlberto, GonzalezTania, Gonzalez-CordonAna, HurtadoCarmen, InciarteAlexy, LagunoMontserrat, LlobetRoger, MallolasJosep, MartinezEsteban, Martinez-RebollarMaria, MiroJose M, MosqueraMar, RodriguezAna, RoviraCristina, Sanchez-PalominoSonsoles, SempereAbiu, SolbesEstela, TorresBerta
Original Abstract of the Article :
BACKGROUND: Decreasing medication burden with raltegravir plus lamivudine in virologically suppressed persons with HIV (PWH) maintained efficacy and was well tolerated at 24 weeks, but more comprehensive data over longer follow-up are required. METHODS: Prospective 48 week extension phase of the ra...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1093/jac/dkad364
データ提供：米国国立医学図書館（NLM）
Raltegravir Plus Lamivudine: A Potential Oasis in the Desert of HIV Management
The fight against HIV is a continuous journey, with researchers constantly seeking new and improved treatment options. This study investigates the efficacy and safety of raltegravir plus lamivudine maintenance therapy in individuals with HIV who have achieved virological suppression.
The study followed 33 individuals with HIV who had achieved virological suppression and were randomized to switch to raltegravir plus lamivudine or continue their current therapy. The results revealed that switching to raltegravir plus lamivudine maintained virological suppression and was well tolerated. This finding suggests that this combination therapy could be a valuable alternative for individuals who need to reduce medication burden, avoid drug-drug interactions, or minimize the potential toxicities of other antiretroviral medications.
Raltegravir Plus Lamivudine: A Promising Maintenance Regimen
This study underscores the potential of raltegravir plus lamivudine as a safe and effective maintenance regimen for individuals with HIV who have achieved virological suppression. It offers a valuable option for simplifying treatment regimens and improving quality of life for these individuals.
Navigating the Desert: Tailoring Treatment to Individual Needs
The study highlights the importance of tailoring treatment plans to individual patient needs. Individuals with HIV may have different preferences, comorbidities, and medication sensitivities. By carefully considering these factors, healthcare providers can choose the most appropriate treatment options for each patient, maximizing the benefits and minimizing the risks.
Dr.Camel's Conclusion
This study offers promising evidence for the efficacy and safety of raltegravir plus lamivudine maintenance therapy in individuals with HIV. This combination therapy could represent a valuable addition to the treatment arsenal, offering a simpler and potentially more convenient option for managing HIV in the long term.
Date :
- Date Completed n.d.
- Date Revised 2023-12-01
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.